TOTOXIC CHEMOTHERAPY regimens used in cancer therapy are often associated with substantial hematopoietic toxicity. Fever and neutropenia (F+N+) are major morbidities that result, and the patient suffers an increased risk of life-threatening infection and prolonged hospitalization. In addition, neutropenia can limit the doses of effective therapy administered. Shortening the length and severity of neutropenia can have major benefits to patients by reducing the risk of infection and perhaps by increasing the amount of chemotherapy that can be administered per unit time. The advent of recombinant DNA technology has allowed the cloning and production of a number of colonystimulating factors for clinical use that can potentially ameliorate much of the hematopoietic toxicity associated with cytotoxic therapy. ' In humans, granulocyte colony-stimulating factor (G-CSF) stimulates the production of functional neutrophils that are protective against infection, and it is safe and effective when administered by either intravenous or subcutaneous routes.2 G-CSF, in conjunction with anticancer chemotherapy, is effective in stimulating granulopoiesis and decreasing the frequency of episodes of F+N+.3-5 G-CSF was used as an adjuvant with methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) chemotherapy for bladder cancer. 6 In this setting, G-CSF decreased the length kg/d) were retreated at the same doses of both drugs; subsequently, 4 of 5 patients had another episode of F + N +.
With flexible G-CSF dosing, taxol dose intensity could be maintained at the target level in 34 of 42 patients (81 % of the cohort). Sixteen of these patients (38% of the cohort) would have required taxol dose reductions for F + N + if flexible G-CSF dosing had not been used. By increasing the G-CSF dose when indicated, patients at high risk for recurrence of F + N +, because they had already experienced one episode, appeared to have a lower risk of developing a recurrent episode. These data suggest that flexible G-CSF dosing may have merit and may allow the administration of more dose-intense taxol. A prospective, randomized, controlled clinical trial of flexible G-CSF dosing versus fixeddose G-CSF appears warranted. This is a US government work. There are no restrictions on its use.
of the white blood cell (WBC) nadir, decreased the frequency of F+N+, and allowed for fewer dose delays of chemotherapy.
G-CSF may also help to achieve dose intensity. Dose-intensive regimens that attempt to increase the doses of chemotherapeutic agents administered during a specific time interval are often associated with greater toxicity, especially neutropenia. In drug-sensitive malignancies, a direct relationship between dose intensity and therapeutic efficacy has been suggested. Adjuvant therapy with cyclophosphamide, doxorubicin, and 5-fluorouracil (CAF) for stage-I1 nodepositive breast cancer administered in a dose-intensive fashion improved the overall disease-free survival of patients, but was associated with grade 3 or 4 neutropenia in 65% of the patient^.^ In patients with non-Hodgkin's lymphoma, retrospective analyses have suggested that increased dose intensity may have resulted in an increased disease response rate.' Also, increased dose intensity of cisplatin, studied by meta-analysis, correlated with an improved response rate in ovarian cancer patients.' In patients with acute myeloid leukemia who are less than 60 years of age, dose-intensive postremission therapy is associated with improved survival." Thus, a wide range of results in a number of different cancer types supports the theory ofdose intensity.
Taxol is a novel chemotherapeutic agent that is active against recurrent ovarian
The dose-limiting toxicity of taxol without G-CSF support is usually neutropenia, which can be readily treated with G-CSF."X'~ We recently developed a higher-dose taxol regimen for patients with advanced epithelial ovarian cancer whose disease is platinumrefra~tory.'~.'~ This report summarizes our efforts to use flexible G-CSF dosing to maintain taxol dose intensity. For personal use only. on September 24, 2017. by guest www.bloodjournal.org From spond to at least one prior platinum-containing regimen were eligible. Patients had to be more than 17 years old, have an ECOG performance status of 22, have objective bidimensional measurable disease, and have received no chemotherapy for at least 4 weeks before starting therapy. Patients must have received no prior external beam radiation therapy. The following laboratory parameters were documented within 1 week of starting therapy: WBC counts r3,000/pL; platelet counts r100,000/pL; serum creatinine 51.5 mg/dL; creatinine clearance 245 mL/min; total bilirubin I 1.5 mg/ dL; and serum transaminases 2 2 times the upper limit of normal. No other chemotherapeutic agents were administered during therapy. Informed consent was obtained from all participating patients.
MATERIALS AND METHODS

Patient
Study design. All patients began treatment at a taxol dose of 250 mg/m2 administered as a 24-hour continuous intravenous (IV) infusion on day 1 repeated every 21 days. G-CSF was administered subcutaneously beginning 24 hours after the completion of the taxol infusion. A complete blood count, including a determination of granulocyte count, was performed every Monday and Thursday. G-CSF administration was continued until the total WBC count was greater than 30,00O/pL for one determination after the WBC nadir or until the total granulocyte count was greater than 3,00O/pL for two successive determinations after the nadir. Patients who had an episode of hematologic toxicity (WBC 11,00O/pL or neutrophils 1500/pL) associated with fever (T > 101.5"F) had their G-CSF dosage increased to 15 Agent preparations used in this study. Taxol was supplied by the Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute (Bethesda, MD). Taxol was formulated as a sterile solution, 6 mg/mL in 5-mL ampules in polyoxyethylated castor oil (Cremophor EL) 50% and dehydrated alcohol, USP, 50%. G-CSF was also supplied by the Developmental Therapeutics Program in vials of0.6 mg/2 mL as a sterile buffered protein solution. The G-CSF was obtained through expression and synthesis in Escherichia coli" and generously provided by Amgen (Thousand Oaks, CA).
RESULTS
Initial patients. The first 5 patients treated in this study to develop F+N+ were retreated at the same dose of taxol (250 mg/m2) and G-CSF (10 pg/kg/d) on subsequent cycles. Five of five patients (100%) developed subsequent neutropenia and 4 of 5 patients (80%) developed another episode of F+N+, including I patient who died from polymicrobial sepsis. Thus patients who had one episode of F+N+ were at high risk for another episode if no dose modifications of taxol or G-CSF were made. This initial experience with a rigid taxol and G-CSF dosing schedule led us to modify our protocol to include flexible G-CSF dosing.
For t Percentage reflects percent relative to total number evaluated at that dose combination.
Patiennt flow through the protocol. Figure 1 shows the flow of patients through the G-CSF treatment schema. Episodes of neutropenia and/or fever. Table I (Table 1) showed 43% of patients treated with 10 pgfkgfd G-CSF had initial episodes of F+N+, whereas at the higher G-CSF dose of l 5 to 20 pg/kg/d, 25% of patients had F+N+.
Eighty-one percent of patients receiving 10 pg/kg/d developed neutropenia, whereas 75% of patients developed neutropenia while receiving 15 to 20 pg/kg/d of G-CSF. Thus, the occurrences of neutropenia were similar in the two groups. Because 4 of the first 5 patients with neutropenia studied at the IO pglkgld G-CSF dose level had repeated episodes of F+N+, we interpret this to suggest that the highrisk group may have been protected by the increases in their G-CSF dose. A similar conclusion can be reached when data are analyzed in terms of cycles of therapy administered (Table l) . An analysis of all cycles was made of patients treated with 250 mg/m2 taxol and either 10 or 15 to 20 pg/kg/d G-CSF. In cycles administered with 10 pg/kg/d G-CSF, 57 of 165 cycles (35%) were associated with neutropenia and 18 cycles ( 1 1%) with F+N+. At the higher G-CSF dose of 15 or 20 pg/ kg/d, 25 of 6 1 cycles (35%) were associated with neutropenia and 6 cycles (10%) were complicated by F+N+. Thus, the two groups seem to be comparable in outcome.
Efects on neutrophil counts. Table 2 shows the analysis of the G-CSF dose effect on neutropenia for all patients treated with a taxol dose of 250 mg/m2 and either 10 or 20 pg/kg/d G-CSF. No significant differences were found in mean neutrophil nadir or day of onset. Note that complete blood counts were obtained on Mondays and Thursdays and were not obtained more frequently unless the patient developed fever. This may have reduced the ability of the study to detect small differences in endpoints. When a patient developed fever, daily counts were obtained until F+N+ resolved. Therefore, a cycle of therapy with docu- For mented fever included a carefully documented WBC nadir after the onset of the fever. Our reported severity and duration of neutropenia may be an underestimation in some patients for these reasons. The average duration of neutropenia in patients receiving taxol (250 mg/m') and G-CSF (10 pg/kg/d) who developed F+N+ was 2.0 f l . l days. Thus, even in patients who developed F+N+, the duration of neutropenia was brief.
G-CSF was administered for an average 7.2 f 1.6 days for patients who did not develop F+N+, and 7.8 f 1.8 days for the 18 patients who did. Figure 2 shows the average number of days that G-CSF was administered for each cycle of therapy for patients receiving 10 pg/kg/d (Fig 2A) or 20 pg/kg/d (Fig 2B) . No significant differences in length of G-CSF administration were found between different cycles of therapy or between the two G-CSF dose levels. The presence of F+N+ during cycle one did not correlate with the number of prior therapies received, which averaged 2.6 (range, 1 to 6) for the patients studied.
DISCUSSION
Our phase I1 study using G-CSF support demonstrated an objective response rate of 50% in patients who had failed to respond to platinum-based therapy, suggesting the need for a trial of high-versus low-dose taxol, because prior small phase I1 trials showed a lower response This trial successfully attempted to test the efficacy of dose-intense taxol. One of the most important obstacles to this trial was the predictable neutropenia that highdose taxol induces.14 We therefore used G-CSF for bone marrow support. After we treated 5 patients on this protocol, we realized that the dose intensity we sought would be difficult to maintain. F+N+ was common, and patients who experienced one episode of F+N+ could not be retreated with taxol at the high dose without a grave risk ofrecurrent F+N+. Consequently, we decided to use flexible G-CSF dosing. This strategy proved to be successful and allowed patients who otherwise may have required dose reductions of taxol to receive continued high-dose therapy. In this study, WBC counts did not differ significantly between the 10 and 20 pg/m2/d doses of G-CSF, suggesting a possible protective effect by the higher G-CSF dose in cycles administered to patients who had already experienced F+N+. Neutrophil function may be responsible in part for the protective effect, because increased function has been observed in vitro with G-CSF administration. ' The optimal dose and schedule of G-CSF that is effective as an adjunct in patients treated with chemotherapy is currently under investigation. G-CSF has been administered in a variety of schedules in patients being treated with chemotherapy. In one of the earliest trials of G-CSF with chemotherapy, patients treated with M-VAC for bladder cancer were treated with G-CSF. Doses from 1 to 60 pg/kg/d were administered as an IV infusion over 30 minutes on days 4 through 1 l of the protocol.6 Pretreatment neutrophil counts were increased in a dose-dependent fashion; neutrophil counts increased 1.9-fold with the administration of 1 pg/ kg/d for 5 days, and up to 10.2-fold with 60 pg/kgld.6 In a randomized, placebo-controlled trial of patients receiving chemotherapy for small cell lung cancer, G-CSF was self-1191 administered subcutaneously in a fixed dosage of 230 pg/ m'/d starting 24 hours after the completion of chemotherapy from day 4 until day l 7.4 This regimen was well tolerated and led to reductions of F+N+ and of documented infections. A wide variety ofschedules ofG-CSF were effective whether administered IV (bolus or continuous) or subcutaneously, and a dose-response relationship (peripheral white blood counts) has been routinely observed, although the effect has not been studied in detail in patients receivingchem~therapy.",~~ The data presented here illustrate one major point. When using a cytotoxic agent in which myelosup pression is the major toxicity, flexible dosing of the appropriate CSF may permit maintained optimal dose intensity.
A G-CSF dose of 5 pg/kg/d has been suggested as an a p propriate dose for chemotherapy trials, but the optimal dose is not yet defined.18 Whereas this may be reasonable for regimens of low or intermediate levels of myelosuppression, more aggressive cytotoxic chemotherapy may require more substantial bone marrow protection. Individualization of therapy with flexible G-CSF doses based on the patient's tol- For personal use only. on September 24, 2017. by guest www.bloodjournal.org From erance and response to chemotherapy may be a new and useful approach. G-CSF dose escalation may be beneficial in some patients, whereas lower doses or no G-CSF may be sufficient in patients with more tolerant bone marrow. Thus, added drug cost and complications can be avoided. Treatment regimens designed with flexible G-CSF dosing tailored to the individual may also allow for more dose-intense therapy that might in turn improve patient survival. Taxol appears to be an important addition to the treatment armamentarium for ovarian and breast c a n~e r l '~'~~~~ and possibly other This study suggests the need for a randomized control trial of fixed dose versus flexible dose G-CSF as an adjunct to dose-intensive chemotherapy with taxol in ovarian cancer patients. A phase 111 intergroup trial has been organized by the Cancer Therapy Evaluation Program of National Cancer Institute that will test these hypotheses.
